ISOFOL.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-0.19	$-0.19–$-0.19	—	2
2027	$33M	—	$-0.03	$-0.03–$-0.03	—	2
2028	$90M	+175.7%	$-0.17	$-0.17–$-0.17	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 5 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-05-19	$-0.47	$-0.05	+88.7%
2026-02-18	$-0.47	$-0.05	+89.4%
2025-11-12	$-0.81	$-0.05	+93.8%
2024-11-12	$-0.42	$-0.07	+84.2%
2024-08-21	$-0.28	$-0.07	+75.3%

DCF fair valuemodel estimate

Intrinsic value

$0.19

Price

$0.73

Implied downside

-74%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ISOFOL.STIsofol Medical AB (publ)	$0.72	-2.59%	$229M	—
ALZ.STAlzinova AB (publ)	$0.46	-0.33%	$47M	—
ANNX.STAnnexin Pharmaceuticals AB	$12.55	-1.18%	$90M	—
BIOWKS.STBio-Works Technologies AB (publ)	$3.30	+2.80%	$273M	—
CLS-B.STClinical Laserthermia Systems AB (publ)

Isofol Medical AB (publ)

Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.

isofolmedical.com

Employees: 7
IPO / List date: Apr 4, 2017
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds ISOFOL.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ISOFOL.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ISOFOL.ST yet.